Finally, the documented evolution of prostate carcinoma lesions from PSMA+/AR-responsive to PSMA+/AR non-responsive followed by a PSMA-, aggressive phenotype, as evidenced by available studies, suggests the use of PSMA-targeted therapies should be upfront rather than at the end of the treatment chain, as is currently the case. Here, FOLH1 is linked to prostate carcinoma.